Autosomal-dominantly inherited forms of Parkinson’s disease

  • T. Gasser
Conference paper


Today, a genetic contribution to the etiology of Parkinson’s disease (PD) is generally accepted, based on the demonstration of a familial aggregation of the disease, as demonstrated by several case-control and twin-studies. However, most cases ofPD appear to be sporadic, and in the majority of those with a positive family history, no clear mendelian mode of inheritance can be established. Therefore, a polygenic mode of inheritance or a multifactorial etiology is likely in these cases.

On the other hand, a number of families have been identified, in whom parkinsonism is inherited as an apparently monogenic mendelian trait with high penetrance. In several of these families, the disease genes have been mapped and mutations have been identified in some of them. The first gene locus has been mapped to the long arm of chromosome 4 in a small number of families with autosomal-dominant inheritance and typical Lewy-body pathology (PARK 1), and mutations have been identified in the gene for α-synuclein in these kindreds. Two other loci in families with dominant inheritance have been mapped, to chromosome 2p13 (PARK 3) and to chromosome 4p, respectively. A gene causing autosomal recessive parkinsonism of juvenile onset has been mapped to chromosome 6 (PARK 2), and the causative gene has been identified and named parkin.

Each of these genetically defined familial disorders share clinical characteristics that fulfill the criteria accepted for idiopathic Parkinson’s disease but, as in sporadic PD, also show a variability of clinical expressions, both within and between families. At present, there is no direct evidence that any of these genes for familial Parkinsonian syndromes have a direct role in the etiology of the common sporadic form of PD. However, the elucidation of the molecular sequence of events leading to nigral degeneration in these inherited cases is likely to shed light also on the molecular pathogenesis of the common sporadic form of this disorder.


Multiple System Atrophy Essential Tremor Postural Tremor Founder Haplotype Nigral Degeneration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexi T, Hefti F (1993) Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture. Neuroscience 55: 903–918PubMedCrossRefGoogle Scholar
  2. Blum M (1998) A null mutation in TGF-alpha leads to a reduchtion in midbrain dopaminergic neurons in the substantia nigra. Nat Neurosci 1: 374–377PubMedCrossRefGoogle Scholar
  3. Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G (1995) Familial Parkinson’s disease: a clinical genetic analysis. Can J Neurol Sci 22: 272–279PubMedGoogle Scholar
  4. Burn D.J., Mark M.H., Playford E.D., Maraganore D.M., Zimmerman T.R. Jr, Duvoisin R.C., Harding A.E., Marsden C.D., Brooks D.J. (1992) Parkinson’s disease in twins studied with 18F-dopa and positron emission tomography. Neurology 42: 1894–1900PubMedCrossRefGoogle Scholar
  5. De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, Marconi R, Castellano A.E., Campanella G (1996) Environmental and genetic risk factors in Parkinson’s disease: a case-control study in southern Italy. Mov Disord 11: 17–23PubMedCrossRefGoogle Scholar
  6. Di Rocco A, Molinari S.P., Kollmeier B, Yahr M.D. (1996) Parkinson’s disease: progression and mortality in the L-DOPA era. Adv Neurol 69: 3–11PubMedGoogle Scholar
  7. Duvoisin R.C., Eldridge R, Williams A, Nutt J, Calne D (1981) Twin study of Parkinson disease. Neurology 31: 77–80PubMedCrossRefGoogle Scholar
  8. El-Agnaf O.M., Jakes R, Curran M.D., Wallace A (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alphasynuclein protein implicated in Parkinson’s disease. FEBS Lett 440: 67–70PubMedCrossRefGoogle Scholar
  9. Farrer L.A., O’Sullivan D.M., Cupples L.A., Growdon J.H., Myers R.H. (1989) Assessment of genetic risk for Alzheimer’s disease among first-degree relatives. Ann Neurol 25:485–493PubMedCrossRefGoogle Scholar
  10. Farrer M, Gwinn-Hardy K, Muenter M, Wavrant D.F., Crook R, Perez-Tur J, Lincoln S, Maraganore D, Adler C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J (1999) A chromosome 4p haplotype segregating with Parkinson’s disease and postural tremor. Hum Mol Genet 8: 81–85PubMedCrossRefGoogle Scholar
  11. Fearnley J.M., Lees A.J. (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114: 2283–2301PubMedCrossRefGoogle Scholar
  12. Gasser T, Müller-Myhsok B, Wszolek Z, Durr A, Vaughan J.R., Bonifati V, Meco G, Bereznai B, Oehlmann R, Agid Y, Brice A, Wood N.W. (1997) Genetic complexity and Parkinson’s disease. Science 277: 388–389PubMedGoogle Scholar
  13. Gasser T, Müller-Myhsok B, Wszolek Z.K., Oehlmann R, Calne D.B., Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann R (1998) A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nature Genet 18: 262–265PubMedCrossRefGoogle Scholar
  14. Gasser T, Bereznai B, Wieditz G, Wszolek Z.K., Mtiller-Myhsok B (1999) Evaluation of a Danish/German founder haplotype at the PARK3-locus on chromosome 2p13. Mov Disord 13: 103 (Abstract)Google Scholar
  15. Gibb W.R., Lees A.J. (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 15: 27–44PubMedCrossRefGoogle Scholar
  16. Golbe L.I., Di Iorio G, Bonavita V, Miller D.C., Duvoisin R.C. (1990) A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol 27: 276–282PubMedCrossRefGoogle Scholar
  17. Golbe L.I., Di Iorio G, Sanges G, Lazzarini A, LaSala S, Bonavita V, Duvoisin R (1996) Clinical genetic analysis of Parkinson’s disease in the Contursi kindred. Ann Neurol 40: 767–775PubMedCrossRefGoogle Scholar
  18. Hashimoto M, Hsu L.J., Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E (1998) Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 799: 301–306PubMedCrossRefGoogle Scholar
  19. Holthoff V.A., Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, Wagner R, Wienhard K, Pawlik G, Heiss W.D. (1994) Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 36: 176–182PubMedCrossRefGoogle Scholar
  20. Ishikawa A, Takahashi H (1998) Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol 245: P4–9PubMedCrossRefGoogle Scholar
  21. Jensen P.H., Nielsen M.S., Jakes R, Dotti C.G., Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation. J Biol Chem 273: 26292–26294PubMedCrossRefGoogle Scholar
  22. Klein C, Vieregge P, Hagenah J, Sieberer M, Doyle E, Jacobs H, et al (1999) Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson’s disease from northern Germany. Ann Hum Genet 63 (Pt 4): 285–291Google Scholar
  23. Koller W.C., Busenbark K, Miner K (1994) The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol 35: 717–723PubMedCrossRefGoogle Scholar
  24. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen J.T., Schöls L, Riess O (1998) Ala39Pro mutation in the gene encoding a-synuclein in Parkinson’s disease. Nature Genet 18: 106–108PubMedCrossRefGoogle Scholar
  25. Lazzarini A.M., Myers R.H., Zimmerman T.R. Jr, Mark M.H., Golbe L.I., Sage J.I., Johnson W.G., Duvoisin R.C. (1994) A clinical genetic study of Parkinson’s disease: evidence for dominant transmission. Neurology 44: 499–506PubMedCrossRefGoogle Scholar
  26. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein M.J., Jonnalagada S, Chemova T, Dehejia A, Lavedan C, Gasser T, Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395: 451–452PubMedCrossRefGoogle Scholar
  27. Lippa C.F., Fujiwara H, Mann D.M., Giasson B, Baba M, Schmidt M.L., Nee L.E., O’Connell B, Pollen D.A., St. George-Hyslop P, Ghetti B, Nochlin D, Bird T.D., Cairns N.J., Lee V.M., Iwatsubo T, Trojanowski J.Q. (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370PubMedCrossRefGoogle Scholar
  28. Marder K, Tang M.X., Mejia H, Alfaro B, Cote L, Louis E, Groves J, Mayeux R (1996) Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology 47: 155–160PubMedCrossRefGoogle Scholar
  29. Markopoulou K, Wszolek Z.K., Pfeiffer R.F. (1995) A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 38: 373–378PubMedCrossRefGoogle Scholar
  30. Marttila R.J., Kaprio J, Koskenvuo M, Rinne U.K. (1988) Parkinson’s disease in a nationwide twin cohort. Neurology 38: 1217–1219PubMedCrossRefGoogle Scholar
  31. Muenter M, Howard F.M. Jr, Okazaki H (1986) A familial Parkinson-dementia syndrome. Neurology 36: 115–115 (Abstract)CrossRefGoogle Scholar
  32. Muenter M.D., Forno L.S., Hornykiewicz O, Kish S.J., Maraganore D.M., Caselli R.J., Okazaki H, Howard F.M. Jr, Snow B.J., Caine D.B. (1998) Hereditary form of parkinsonism-dementia. Ann Neurol 43: 768–781PubMedCrossRefGoogle Scholar
  33. Payami H, Larsen K, Bernard S, Nutt J (1994) Increased risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol 36: 659–661PubMedCrossRefGoogle Scholar
  34. Piccini P, Morrish P.K., Turjanski N, Sawle G.V., Burn D.J., Weeks R.A., Mark M.H., Maraganore D.M., Lees A.J., Brooks D.J. (1997) Dopaminergic function in familial Parkinson’s disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 41: 222–229PubMedCrossRefGoogle Scholar
  35. Piccini P, Burn D.J., Ceravolo R, Brooks D.J. (1998) F-dopa PET studies in discordant twins with Parkinson’s disease: a follow-.up. J Neurol 245: 364 (Abstract)Google Scholar
  36. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G, Sanges G, Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., Duvoisin R (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274:1197–1199PubMedCrossRefGoogle Scholar
  37. Polymeropoulos M.H., Lavedan C, Leroy E, Ide S.E., Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos E.S., Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G, Nussbaum R.L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276: 2045–2047PubMedCrossRefGoogle Scholar
  38. Rajput A.H., Moghal S, Rajput A (1994) Parkinson’s disease and essential tremor. Neurology 44: 778–778PubMedCrossRefGoogle Scholar
  39. Scott W.K., Stajich J.M., Yamaoka L-H, Speer M.C., Vance J.M., Roses A.D., Pericak Vance M.A. (1997) Genetic complexity in Parkinson’s disease. Science 277: 387–388PubMedCrossRefGoogle Scholar
  40. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840PubMedCrossRefGoogle Scholar
  41. Tanner C.M., Ottman R, Goldman S.M., Ellenberg J, Chan P, Mayeux R, et al (1999) Parkinson disease in twins: an etiologic study. JAMA 281(4): 341–346PubMedCrossRefGoogle Scholar
  42. Tu P.H., Galvin J.E., Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski J.Q., Lee V.M. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44: 415–422PubMedCrossRefGoogle Scholar
  43. Vaughan J.R., Durr A, Gasser T, Bonifati V, De Michele G, Breteler M.M., Bandmann O, Johnson W, Golbe L.I., Brice A, Wood N (1998a) The α-synuclein Ala53Thr mutation is not a common cause of familial Parkinson’s disease: a study of 230 European cases. Ann Neurol 44: 270–273PubMedCrossRefGoogle Scholar
  44. Vaughan J.R., Farrer M, Wszolek E.K., Gasser T, Durr A, Agid Y, Bonifati V, De Michele G, Volpe G, Lincoln S, Breteler M, Meco G, Brice A, Marsden C.D., Hardy J, Wood N.W. (1998b) Sequencing of the alpha-synuclein gene in a large series of families with familial Parkinson’s disease fails to reveal any further mutations. Hum Mol Genet 7:751–753PubMedCrossRefGoogle Scholar
  45. Vieregge P, Heberlein I (1995) Increased risk of Parkinson’s disease in relatives of patients. Ann Neurol 37: 685–685PubMedCrossRefGoogle Scholar
  46. Ward C.D., Duvoisin R.C., Ince S.E., Nutt J.D., Eldridge R, Calne D.B. (1983) Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 33: 815–824PubMedCrossRefGoogle Scholar
  47. Wszolek Z.K., Pfeiffer R.F., Bhatt M.H., Schelper R.L., Cordes M, Snow B.J., Rodnitzky R.L., Wolters E.C., Arwert F, Calne D.B. (1992) Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann Neurol 32:312–320PubMedCrossRefGoogle Scholar
  48. Wszolek Z.K., Cordes M, Calne D.B., Munter M.D., Cordes I, Pfeifer R.F. (1993) Hereditary Parkinson disease: report of 3 families with dominant autosomal inheritance. Nervenarzt 64: 331–335PubMedGoogle Scholar
  49. Wszolek Z.K., Pfeiffer B, Fulgham J.R., Parisi J.E., Thompson B.M., Uitti R.J., Calne D.B., Pfeiffer R.F. (1995) Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 45: 502–505PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • T. Gasser
    • 1
  1. 1.Department of Neurology, Klinikum GrosshadernLudwig-Maximilians-UniversitätMünchenFederal Republic of Germany

Personalised recommendations